CytRx Corporation (CYTR) Announces the Presentation of Favorable Results From Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at American Society of Clinical Oncology Conference
6/3/2013 7:21:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that preliminary results from a Phase 1b clinical trial determined that aldoxorubicin, the Company’s improved version of the widely used chemotherapeutic agent doxorubicin, administered at 90% of its single agent dose can be safely delivered in combination with doxorubicin administered at 50% of its single agent dose to patients with advanced solid tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by